La cadena de opciones muestra datos clave de las opciones de acciones de DoorDash a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para DoorDash..

DoorDash (NASDAQ:DASH) Bolsa, Cadena de Opciones

DoorDash

Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the US. Through the acquisition of Wolt in 2022, the firm also provides this service in Europe. DoorDash provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers.

ABNB

AMZN

DASH

SMCI

TSLA

Descubre cómo ciertas empresas lograron superar las expectativas en medio de un mercado incierto y una posible contracción económica.

Empresas estadounidenses que superan las previsiones pese al desplome del S&amp;P 500

News

Short Ideas

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

Ventas recientes de insiders en Bank of America, Royal Caribbean, DoorDash y Dropbox, y lo que esto podría significar para los inversores.

Bank of America, Dropbox y otras 2 acciones que los insiders están vendiendo

DoorDash Inc

Dash - United States Dollar

<p>Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) will release its quarterly earnings report on Monday, 2024-11-11. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Live Nation Entertainment to report an <strong>earnings per share</strong> (EPS) of $1.71.</p>
<p>Live Nation Entertainment bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company missed EPS by $0.04, which was followed by a 1.66% increase in the share price the next day.</p>
<p>Here's a look at Live Nation Entertainment's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.07</td>
<td>-0.19</td>
<td>-1.03</td>
<td>1.27</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.03</td>
<td>-0.53</td>
<td>-1.22</td>
<td>1.78</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>7.000000000000001%</td>
<td>2.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731078152_0.png" alt="eps graph" /></p>
<h3>Tracking Live Nation Entertainment's Stock Performance</h3>
<p>Shares of Live Nation Entertainment were trading at $124.6 as of November 07. Over the last 52-week period, shares are up 40.23%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/LYV/earnings"><strong>To track all earnings releases for Live Nation Entertainment visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

What's Next: Live Nation Entertainment's Earnings Preview

<p>Gatos Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GATO#NYSE">GATO</a>) is gearing up to announce its quarterly earnings on Monday, 2024-11-11. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Gatos Silver will report an <strong>earnings per share</strong> (EPS) of $0.14.</p>
<p>The market awaits Gatos Silver's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.02, leading to a 6.65% drop in the share price on the subsequent day.</p>
<p>Here's a look at Gatos Silver's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.15</td>
<td>0.02</td>
<td>0.09</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.13</td>
<td>0.04</td>
<td>0.18</td>
<td>0.05</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>2.0%</td>
<td>-1.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731078145_0.png" alt="eps graph" /></p>
<h3>Performance of Gatos Silver Shares</h3>
<p>Shares of Gatos Silver were trading at $17.03 as of November 07. Over the last 52-week period, shares are up 244.1%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/GATO/earnings"><strong>To track all earnings releases for Gatos Silver visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


GATO

Gatos Silver Earnings Preview

<p>Over the past 24 hours, <strong>Internet Computer's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ICP</a>) price has risen 3.8% to <strong>$7.87</strong>. This is contrary to its negative trend over the past week where it has experienced a 1.0% loss, moving from $8.01 to its current price. As it stands right now, <strong>the coin's all-time high is $700.65</strong>. </p>
<p>The chart below compares the price movement and volatility for Internet Computer over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731078139_0.png" alt="price_chart" /></p>
<p>Internet Computer's trading volume has climbed 57.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has increased 0.59%. This brings the circulating supply to 473.94 million. According to our data, the current market cap ranking for ICP is #30 at $3.73 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731078139_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

$ICP

Cryptocurrency Internet Computer Up More Than 3% In 24 hours

<p>Over the past 24 hours, <strong>NEAR Protocol's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/near/usd">NEAR</a>) price has risen 3.95% to <strong>$4.29</strong>. This continues its positive trend over the past week where it has experienced a 7.0% gain, moving from $4.08 to its current price. As it stands right now, <strong>the coin's all-time high is $20.44</strong>. </p>
<p>The chart below compares the price movement and volatility for NEAR Protocol over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731078129_0.png" alt="price_chart" /></p>
<p>The trading volume for the coin has increased 41.0% over the past week, while the overall circulating supply of the coin has decreased 0.24%. The current market cap ranking for NEAR is #26 at $5.26 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731078129_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$NEAR

Cryptocurrency NEAR Protocol Rises More Than 3% In 24 hours

<p>Bioceres Crop Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOX#NASDAQ">BIOX</a>) is gearing up to announce its quarterly earnings on Monday, 2024-11-11. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Bioceres Crop Solutions will report an <strong>earnings per share</strong> (EPS) of $0.09.</p>
<p>Bioceres Crop Solutions bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company missed EPS by $0.27, leading to a 13.41% drop in the share price the following trading session.</p>
<p>Here's a look at Bioceres Crop Solutions's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.24</td>
<td>0.170</td>
<td>0.09</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.03</td>
<td>0.139</td>
<td>0.02</td>
<td>-0.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-13.0%</td>
<td>-3.0%</td>
<td>7.000000000000001%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731078126_0.png" alt="eps graph" /></p>
<h3>Market Performance of Bioceres Crop Solutions's Stock</h3>
<p>Shares of Bioceres Crop Solutions were trading at $6.57 as of November 07. Over the last 52-week period, shares are down 38.27%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analysts' Take on Bioceres Crop Solutions</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Bioceres Crop Solutions.</p>
<p>The consensus rating for Bioceres Crop Solutions is Buy, derived from 6 analyst ratings. An average one-year price target of $12.92 implies a potential 96.65% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Intrepid Potash, FMC and Mosaic, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Intrepid Potash is maintaining an Sell status according to analysts, with an average 1-year price target of $19.0, indicating a potential 189.19% upside.</li>
<li>The prevailing sentiment among analysts is an Neutral trajectory for FMC, with an average 1-year price target of $69.25, implying a potential 954.03% upside.</li>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Mosaic, with an average 1-year price target of $29.4, implying a potential 347.49% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary outlines pivotal metrics for Intrepid Potash, FMC and Mosaic, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bioceres Crop Solutions</td>
<td>Buy</td>
<td>18.31%</td>
<td>$46.66M</td>
<td>-0.49%</td>
</tr>
<tr>
<td>Intrepid Potash</td>
<td>Sell</td>
<td>5.66%</td>
<td>$7.73M</td>
<td>-0.27%</td>
</tr>
<tr>
<td>FMC</td>
<td>Neutral</td>
<td>8.50%</td>
<td>$386.40M</td>
<td>1.41%</td>
</tr>
<tr>
<td>Mosaic</td>
<td>Neutral</td>
<td>-17.01%</td>
<td>$394M</td>
<td>-1.36%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Bioceres Crop Solutions ranks highest in Revenue Growth among its peers. It has the highest Gross Profit margin. However, it has the lowest Return on Equity.</p>
<h3>Unveiling the Story Behind Bioceres Crop Solutions</h3>
<p>Bioceres Crop Solutions Corp is a fully-integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. The business divisions consist of crop protection, seed and integrated products, and crop nutrition. The company derives majority of its revenue from the crop protection division. Its product includes fertilizers, inoculants, adjuvants, crop protection solutions and seeds.</p>
<h3>Bioceres Crop Solutions's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Bioceres Crop Solutions's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>18.31%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Bioceres Crop Solutions's net margin excels beyond industry benchmarks, reaching <strong>-1.23%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Bioceres Crop Solutions's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-0.49%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Bioceres Crop Solutions's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.18%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.86</strong>, caution is advised due to increased financial risk.</p>
<p><a href="https://www.benzinga.com/quote/BIOX/earnings"><strong>To track all earnings releases for Bioceres Crop Solutions visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BIOX

Examining the Future: Bioceres Crop Solutions's Earnings Outlook

WIIM

Sweetgreen shares are trading lower after Goldman Sachs downgraded the stock from Buy to Neutral.

<p>RMR Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMR#NASDAQ">RMR</a>) will release its quarterly earnings report on Monday, 2024-11-11. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate RMR Gr to report an <strong>earnings per share</strong> (EPS) of $0.38.</p>
<p>RMR Gr bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company missed EPS by $0.02, which was followed by a 0.95% drop in the share price the next day.</p>
<p>Here's a look at RMR Gr's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.39</td>
<td>0.40</td>
<td>0.45</td>
<td>0.45</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.37</td>
<td>0.39</td>
<td>0.49</td>
<td>0.48</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-3.0%</td>
<td>4.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731078118_0.png" alt="eps graph" /></p>
<h3>RMR Gr Share Price Analysis</h3>
<p>Shares of RMR Gr were trading at $24.44 as of November 07. Over the last 52-week period, shares are up 6.62%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/RMR/earnings"><strong>To track all earnings releases for RMR Gr visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Uncovering Potential: RMR Gr's Earnings Preview

<p>Global Ship Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSL#NYSE">GSL</a>) is gearing up to announce its quarterly earnings on Monday, 2024-11-11. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Global Ship Lease will report an <strong>earnings per share</strong> (EPS) of $2.47.</p>
<p>Investors in Global Ship Lease are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.17, leading to a 6.39% increase in the share price the following trading session.</p>
<p>Here's a look at Global Ship Lease's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.29</td>
<td>2.27</td>
<td>2.35</td>
<td>2.15</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.46</td>
<td>2.53</td>
<td>2.49</td>
<td>2.33</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>6.0%</td>
<td>2.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731078112_0.png" alt="eps graph" /></p>
<h3>Performance of Global Ship Lease Shares</h3>
<p>Shares of Global Ship Lease were trading at $24.73 as of November 07. Over the last 52-week period, shares are up 41.52%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/GSL/earnings"><strong>To track all earnings releases for Global Ship Lease visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


What to Expect from Global Ship Lease's Earnings

<p>Sapiens Intl Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPNS#NASDAQ">SPNS</a>) is preparing to release its quarterly earnings on Monday, 2024-11-11. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Sapiens Intl Corp to report an <strong>earnings per share</strong> (EPS) of $0.38.</p>
<p>The market awaits Sapiens Intl Corp's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS beat by $0.01 in the last quarter, leading to a 1.16% drop in the share price on the following day.</p>
<p>Here's a look at Sapiens Intl Corp's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.36</td>
<td>0.34</td>
<td>0.34</td>
<td>0.34</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.37</td>
<td>0.36</td>
<td>0.36</td>
<td>0.34</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>2.0%</td>
<td>1.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731078104_0.png" alt="eps graph" /></p>
<h3>Performance of Sapiens Intl Corp Shares</h3>
<p>Shares of Sapiens Intl Corp were trading at $39.48 as of November 07. Over the last 52-week period, shares are up 56.05%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SPNS/earnings"><strong>To track all earnings releases for Sapiens Intl Corp visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SPNS

Earnings Outlook For Sapiens Intl Corp

<p>Benchmark  analyst Daniel Kurnos   maintains Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) with a Buy and lowers the price target from $10 to $8.</p>


Price Target

Analyst Ratings

SEAT

Benchmark Maintains Buy on Vivid Seats, Lowers Price Target to $8

<p>Scotiabank  analyst Sung Ji Nam   maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Sector Outperform and raises the price target from $40 to $44.</p>


VCYT

Scotiabank Maintains Sector Outperform on Veracyte, Raises Price Target to $44

<p>Truist Securities  analyst Mark Hughes   maintains Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) with a Buy and raises the price target from $300 to $340.</p>


Truist Securities Maintains Buy on Primerica, Raises Price Target to $340

<p>VAALCO Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGY#NYSE">EGY</a>) will release its quarterly earnings report on Monday, 2024-11-11. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate VAALCO Energy to report an <strong>earnings per share</strong> (EPS) of $0.17.</p>
<p>The announcement from VAALCO Energy is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS beat by $0.09 in the last quarter, leading to a 8.38% increase in the share price on the following day.</p>
<p>Here's a look at VAALCO Energy's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.13</td>
<td>0.20</td>
<td>0.12</td>
<td>0.20</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.22</td>
<td>0.06</td>
<td>0.37</td>
<td>0.07</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>8.0%</td>
<td>-4.0%</td>
<td>20.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731078098_0.png" alt="eps graph" /></p>
<h3>Market Performance of VAALCO Energy's Stock</h3>
<p>Shares of VAALCO Energy were trading at $5.6 as of November 07. Over the last 52-week period, shares are up 35.52%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/EGY/earnings"><strong>To track all earnings releases for VAALCO Energy visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


What's Next: VAALCO Energy's Earnings Preview

<p>Assured Guaranty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGO#NYSE">AGO</a>) will release its quarterly earnings report on Monday, 2024-11-11. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Assured Guaranty to report an <strong>earnings per share</strong> (EPS) of $1.36.</p>
<p>The announcement from Assured Guaranty is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS beat by $0.11 in the last quarter, leading to a 2.37% drop in the share price on the following day.</p>
<p>Here's a look at Assured Guaranty's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.33</td>
<td>1.32</td>
<td>1.18</td>
<td>1.05</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.44</td>
<td>1.96</td>
<td>5.75</td>
<td>3.42</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>5.0%</td>
<td>11.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731078090_0.png" alt="eps graph" /></p>
<h3>Market Performance of Assured Guaranty's Stock</h3>
<p>Shares of Assured Guaranty were trading at $86.53 as of November 07. Over the last 52-week period, shares are up 33.43%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/AGO/earnings"><strong>To track all earnings releases for Assured Guaranty visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights into Assured Guaranty's Upcoming Earnings

GSAT

Globalstar shares are trading higher after the company reported better-than-expected Q3 sales results and raised its FY24 sales guidance.

<p>NET Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPWR#NYSE">NPWR</a>) is preparing to release its quarterly earnings on Monday, 2024-11-11. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect NET Power to report an <strong>earnings per share</strong> (EPS) of $-0.09.</p>
<p>Investors in NET Power are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company beat EPS by $0.03, which was followed by a 6.36% increase in the share price the next day.</p>
<p>Here's a look at NET Power's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.09</td>
<td>-0.25</td>
<td>-0.05</td>
<td>-0.05</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.06</td>
<td>-0.16</td>
<td>0.34</td>
<td>-0.44</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>6.0%</td>
<td>8.0%</td>
<td>-1.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731078072_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of NET Power were trading at $9.23 as of November 07. Over the last 52-week period, shares are down 31.31%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/NPWR/earnings"><strong>To track all earnings releases for NET Power visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


NPWR

A Peek at NET Power's Future Earnings

<p>In the last three months, 3 analysts have published ratings on Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Agilon Health and provided 12-month price targets. The average target is $3.17, accompanied by a high estimate of $4.00 and a low estimate of $2.50. A 54.71% drop is evident in the current average compared to the previous average price target of $7.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731078069_0_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of Agilon Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$2.50</td>
<td>$7.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$4.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$3.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Agilon Health. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Agilon Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Agilon Health's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into Agilon Health's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AGL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Agilon Health analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Agilon Health</h2>
<p>Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.</p>
<h3>Financial Insights: Agilon Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Agilon Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>38.69%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Agilon Health's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-2.07%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Agilon Health's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-4.49%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Agilon Health's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-1.37%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.07</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Landscape: 3 Takes On Agilon Health

<p>Luminar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) is preparing to release its quarterly earnings on Monday, 2024-11-11. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Luminar Technologies to report an <strong>earnings per share</strong> (EPS) of $-0.17.</p>
<p>The announcement from Luminar Technologies is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.01, which was followed by a 37.36% drop in the share price the next day.</p>
<p>Here's a look at Luminar Technologies's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.19</td>
<td>-0.20</td>
<td>-0.19</td>
<td>-0.22</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.18</td>
<td>-0.19</td>
<td>-0.20</td>
<td>-0.21</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-37.0%</td>
<td>19.0%</td>
<td>-5.0%</td>
<td>-15.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731078064_0.png" alt="eps graph" /></p>
<h3>Performance of Luminar Technologies Shares</h3>
<p>Shares of Luminar Technologies were trading at $0.8911 as of November 07. Over the last 52-week period, shares are down 70.13%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/LAZR/earnings"><strong>To track all earnings releases for Luminar Technologies visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


LAZR

An Overview of Luminar Technologies's Earnings

<p>In the latest quarter, 6 analysts provided ratings for TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $9.5, a high estimate of $12.00, and a low estimate of $5.00. A 21.94% drop is evident in the current average compared to the previous average price target of $12.17. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731078063_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of TELA Bio among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$5.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Caitlin Cronin</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$12.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Frank Takkinen</td>
<td>Lake Street</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Caitlin Cronin</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to TELA Bio. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of TELA Bio compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of TELA Bio's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of TELA Bio's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TELA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on TELA Bio analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into TELA Bio's Background</h2>
<p>TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. The company's second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, addresses unmet needs in plastic and reconstructive surgery.</p>
<h3>Financial Milestones: TELA Bio's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> TELA Bio displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>11.02%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> TELA Bio's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-78.3%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> TELA Bio's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-146.05%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> TELA Bio's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-19.09%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>14.42</strong>, caution is advised due to increased financial risk.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TELA

Deep Dive Into TELA Bio Stock: Analyst Perspectives (6 Ratings)

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Palantir Technologies</strong>.</p>
<p>Looking at options history for Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) we detected 11 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 63% of the investors opened trades with bullish expectations and 18% with bearish.</p>
<p>From the overall spotted trades, 2 are puts, for a total amount of $163,622 and 9, calls, for a total amount of $571,043.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $10.0 and $60.0 for Palantir Technologies, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Palantir Technologies's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Palantir Technologies's significant trades, within a strike price range of $10.0 to $60.0, over the past month.</p>
<h3>Palantir Technologies Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731078055_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$16.6</td>
<td>$13.45</td>
<td>$14.77</td>
<td>$41.00</td>
<td>$147.7K</td>
<td>7.2K</td>
<td>101</td>
</tr>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$1.14</td>
<td>$1.12</td>
<td>$1.12</td>
<td>$55.00</td>
<td>$112.1K</td>
<td>10.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.1</td>
<td>$60.00</td>
<td>$60.1K</td>
<td>16.2K</td>
<td>113</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$10.9</td>
<td>$10.9</td>
<td>$10.9</td>
<td>$45.00</td>
<td>$58.4K</td>
<td>504</td>
<td>28</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$15.05</td>
<td>$14.55</td>
<td>$14.55</td>
<td>$42.00</td>
<td>$58.2K</td>
<td>7.7K</td>
<td>46</td>
</tr>
</tbody>
</table>
</p>
<h3>About Palantir Technologies</h3>
<p>Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. The Denver-based company was founded in 2003 and went public in 2020.</p>
<p>Having examined the options trading patterns of Palantir Technologies, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Palantir Technologies</h3>
<ul>
<li>Trading volume stands at 42,321,749, with PLTR's price down by -2.72%, positioned at $54.02.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 87 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Palantir Technologies with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

PLTR

A Closer Look at Palantir Technologies's Options Market Dynamics

Barclays analyst Ross Sandler maintained a Hold rating on DoorDash (DASH – Research Report) today and set a price target of $163.00. The company's ...

Barclays Sticks to Its Hold Rating for DoorDash (DASH)

In a report released yesterday, Ken Gawrelski from Wells Fargo maintained a Hold rating on DoorDash (DASH – Research Report), with a price target o...

DoorDash (DASH) Gets a Hold from Wells Fargo

Barclays analyst Ross Sandler raised the firm's price target on DoorDash (DASH) to $163 from $120 and keeps an Equal Weight rating on the shares. T...

DoorDash price target raised to $163 from $120 at Barclays

In a report released yesterday, Tom White from D.A. Davidson maintained a Hold rating on DoorDash (DASH – Research Report). The company's shares cl...

DoorDash (DASH) Receives a Hold from D.A. Davidson

DoorDash: Stock Should Keep Climbing Higher As Revenue And Free Cash Flow Take Off

In a report released yesterday, Jake Fuller from BTIG maintained a Buy rating on DoorDash (DASH – Research Report), with a price target of $175.00....

DoorDash (DASH) Receives a Buy from BTIG

Cheesecake Factory: Menu Price Increases Continue To Offset Negative Mix In Q3

Tracking Baillie Gifford's 13F Portfolio - Q3 2024 Update

In a report released yesterday, Youssef Squali from Truist Financial maintained a Buy rating on DoorDash (DASH – Research Report), with a price tar...

DoorDash (DASH) Receives a Buy from Truist Financial

BMO Capital raised the firm's price target on Lyft (LYFT) to $18 from $13 and keeps a Market Perform rating on the shares. The company's Q3 Booking...

Comments

DoorDash

DoorDash (DASH) Opciones

DoorDash (NASDAQ:DASH) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL